The $34 billion private equity powerhouse H.I.G. Capital announced the acquisition of BioVectra in a bid to further expand the Canadian company’s biopharmaceutical business.
Continue Reading With a Free Trial
Unlock this article instantly, along with the rest of our premium content, newsletters and mandate charts.
Already a subscriber? Log in.